In vitro inhibitory effect of carrageenan oligosaccharide on influenza A H1N1 virus
Highlights
► Carrageenan oligosaccharide CO-1 effectively inhibits IAV replication in vitro. ► Oligosaccharide CO-1 does not interfere with IAV adsorption and internalization. ► CO-1 mainly blocks an early step in IAV replication after virus internalization. ► CO-1 inhibits IAV mRNA and protein expression after its internalization into cells.
Introduction
Influenza A virus (IAV) is a most formidable pathogen, which has been the cause of at least three pandemics in the last century. The most severe IAV pandemic caused more than 40 million deaths in the world during 1918–1919 (Lamb and Takeda, 2001, Yewdell and Garcia-Sastre, 2002). In late April 2009, a novel influenza A (H1N1) virus caused a pandemic in a short period of time, which attracted great attention all over the world. Current anti-IAV drugs are directed against the M2 protein (adamantanes) and neuraminidase (NA; zanamivir and oseltamivir) (Hay et al., 1985, Mendel et al., 1998). Despite these successes, the drug efficacy, resistance, toxicity, and cost remained to be unresolved issues (Hayden and Pavia, 2006). Recently, several other approaches including inhibitors of viral RNA transcription, small interfering RNA, inhibitors of virus-cell fusion or proteolytic processing of HA have been developed, but so far none of inhibitors have been developed into a drug (Lagoja and De Clercq, 2008). Hence, the development of novel antiviral agents that could be used alone or in combination with existing antiviral drugs is of high importance.
Carrageenan polysaccharide, extracted from red algae, shows different inhibitory effects on different viruses (Buck et al., 2006, Carlucci et al., 2004, Grassauer et al., 2008, Pujol et al., 2006, Talarico and Damonte, 2007). Previous studies have shown that carrageenan inhibits the replication of some enveloped viruses by interfering with virus adsorption and internalization into host cells (Buck et al., 2006, Grassauer et al., 2008, Talarico and Damonte, 2007). However, other reports have shown that carrageenan does not inhibit virus adsorption but inhibits some steps of virus life cycle in host cells (Gonzalez et al., 1987, Pujol et al., 2006). Recently, Leibbrandt et al. reported that ι-carrageenan polysaccharide could inhibit influenza A virus infection by directly binding to the virus particles (Leibbrandt et al., 2010), while Talarico et al. found that carrageenan could inhibit dengue virus infection in mosquito cells by targeting cellular proteins (Talarico et al., 2011). The inhibitory mechanism of carrageenans on virus replication seems to be dependent on the type of polysaccharide (Damonte et al., 2004) as well as the serotype of the virus and the host cells (Girond et al., 1991). Despite having good inhibitory effects on virus replication, the high molecular weight (MW) associated poor tissue-penetrating ability of sulfated polysaccharides limits their potential antiviral application in humans.
In recent years, marine oligosaccharides are attracting increasing interests in developing potential anti-viral drugs (Ji et al., 2011). Yamada et al. reported that O-acylated carrageenan oligosaccharides with different MW had increased anti-HIV activities after depolymerization and sulfation (Yamada et al., 1997, Yamada et al., 2000). Ekblad et al. found that heparan sulfate (HS) mimetic PI-88, a sulfomannan oligosaccharide of low MW, efficiently reduced the cell-to-cell spread of herpes simplex virus (HSV) (Ekblad et al., 2010, Nyberg et al., 2004). The low-viscosity and high-solvency of marine oligosaccharides at neutral pH also suggest their potential use as anti-viral drugs. However, the molecular mechanisms underlying the anti-viral effects of oligosaccharides have not been systematically pursued.
In the present study, we investigated the capacity and molecular mechanisms of κ-carrageenan derived oligosaccharides in inhibiting IAV infection. Our results indicated that carrageenan oligosaccharide with low molecular weight (∼2 kDa) could effectively inhibit IAV replication in vitro. IAV multiplication was suppressed by carrageenan oligosaccharide treatment in a dose-dependent manner. Carrageenan oligosaccharide CO-1 did not bind to the cell surface of MDCK cells but inactivated virus particles after pretreatment. CO-1 could enter into MDCK cells and did not interfere with IAV adsorption directly. Moreover, carrageenan oligosaccharide also inhibited IAV mRNA and protein expression after its internalization into cells.
Section snippets
Compounds and reagents
The κ-carrageenan-derived oligosaccharides named CO-1, CO-2, CO-3 and FITC-labeled oligosaccharide (CO-1-FITC) were provided by Glycoscience and Glycoengineering Laboratory, school of Medicine and Pharmacy, Ocean university of China. Mouse anti-influenza A virus nucleoprotein (NP) and anti-β-actin monoclonal antibodies were purchased from Santa Cruz Biotechnology (USA). Rabbit anti-influenza A virus neuraminase (NA) polyclonal antibody was purchased from Abcam (Hong Kong, China). FITC-labeled
Characterization of carrageenan oligosaccharides
Carrageenan oligosaccharides were prepared and depolymerized by acidic hydrolysis of κ-carrageenan followed by fractionation using chromatographic separation. The molecular weights of κ-carrageenan oligosaccharides CO-1, CO-2 and CO-3 were determined by HPLC based on the calibration with dextran standards as described before (Yamamoto et al., 1995). The average molecular weight of κ-carrageenan oligosaccharide CO-1 was about 2 kDa. The degree of polymerization (DP) of CO-1 was about 3–13 (Fig. 1
Discussion
Recently, marine oligosaccharides and their derivatives have been attracting increasing interest in developing potential anti-viral drugs (Artan et al., 2010, Ji et al., 2011). In this study, carrageenan derived oligosaccharide CO-1, a low molecular weight fragment of κ-carrageenan (∼2 kDa), was demonstrated to be able to effectively suppress the replication of influenza A virus in MDCK cells (IC50 < 35 μg/mL). In contrast, the carrageenan oligosaccharides with higher molecular weights (CO-2, CO-3)
Conflict of interest statement
None declared.
Acknowledgments
We thank Prof. Lijuan Zhang (Ocean University of China, PRC) for her helpful advice and critical readings of the manuscript. This work was supported in part by the Program for Changjiang Scholars and Innovative Research Team in University (IRT0944), the Fundamental Research Funds for the Central Universities (201113013), Shandong Provincial Natural Science Foundation (ZR2011HQ012), and Special Fund for Marine Scientific Research in the Public Interest (201005024). Z.-Q. C. is supported by
References (39)
- et al.
Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides
Carbohydr. Res.
(2010) - et al.
Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice
Antiviral Res.
(2004) - et al.
A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus
Antiviral Res.
(2010) - et al.
Influence of molecular structure imaged with atomic force microscopy on the rheological behavior of carrageenan aqueous system in the presence or absence of cations
Food Hydrocolloid.
(2007) - et al.
Antiviral activity of carrageenan on hepatitis A virus replication in cell culture
Res. Virol.
(1991) - et al.
Aurintricarboxylic acid inhibits influenza virus neuraminidase
Antiviral Res.
(2009) - et al.
Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method
Methods
(2001) - et al.
Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome (AIDS) drug candidate, targeting CD4 in lymphocytes
Biochem. Pharmacol.
(2004) - et al.
Synthesis of β-(1 → 6)-Branched β-(1 → 3) glucohexaose and its analogues containing an α-(1 → 3) linked bond with antitumor activity
Bioorg. Med. Chem.
(2003) - et al.
The low molecular weight heparan sulfate mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus
Antiviral Res.
(2004)